Download Free The Politics Of Breast Cancer Book in PDF and EPUB Free Download. You can read online The Politics Of Breast Cancer and write the review.

Between 1990 and 1993, breast cancer activism became a significant political movement. The issue began to receive extensive media attention, and federal funding for breast cancer research jumped dramatically. Describing the origins of this surge in interest, Maureen Hogan Casamayou attributes it to the emergence of politically potent activism among breast cancer survivors and their supporters. Exploring the creation and development of the National Breast Cancer Coalition (NBCC), she shows how many of its key leaders were mobilized by their own traumatic experiences with the disease and its treatments. Casamayou details the NBCC’s meteoric rise and impressive lobbying efforts, explaining how—in contrast to grassroots movements founded by dedicated individuals—the coalition grew from the simultaneous efforts of a network of women who invested their time, energy, money, and professional skills in the fight for increased funding for breast cancer research. This multiple leadership—or collective entrepreneurialism, says Casamayou—was crucial to the NBCC’s success framing the issue in the minds of the public and policymakers alike.
The commercialization of the breast cancer movement is challenged in this analysis of how breast cancer has been transformed from a stigmatized disease and individual tragedy to a market-driven industry of survivorship.
Hiding Politics in Plain Sight examines the costs of market mechanisms, especially cause marketing, as a strategy for change. Industry and corporate-connected individuals use market mechanisms to brand issues like breast cancer widely, shaping public understanding. But framed as consensus-based social issues rather than contentious political issues, they essentially hide politics in plain sight.
"The Politics of Cancer Revisited," by internationally renowned authority on cancer causes and preventions, Samuel S. Epstein, M.D., backed by meticulous documentation, charges that the cancer establishment remains myopically fixated on damage control--diagnosis and treatment, and basic genetic research with, not always benign, indifference to cancer prevention research and failure of outreach to Congress, regulatory agencies, and the public with scientific information on unwitting exposures to a wide range of avoidable causes of cancer. The National Cancer Institute (NCI) and the American Cancer Society (ACS) are also accused of pervasive conflicts of interest, particularly with the cancer drug industry.
A breast cancer survivor shares her own family history with breast cancer, providing a feminist assessment of the causes, politics, and economics of breast cancer. Explored are such factors as carcinogens and the environment, racial components, domination of the medical field by corporate interests, the issue of breast reconstruction, and other topics. c. Book News Inc.
Scientific Characters chronicles the contests over character, knowledge, trust, and truth in a politically charged scientific controversy that erupted after a 1994 Chicago Tribune headline: "Fraud in Breast Cancer Research: Doctor Lied on Data for Decade." Moving back and forth between news coverage, medical journals, letters to the editor, and oncology pamphlets, Lisa Keränen draws insights from rhetoric, literary studies, sociology, and science studies to analyze the roles of character in shaping the outcomes of the "Datagate" controversy.
Kate Pickert worked as a health-care journalist and knew medical treatment well, but it all changed when she was diagnosed with an aggressive type of breast cancer at age 35. Pickert used her journalistic skills to identify the cultural, scientific, and historical forces shaping the lives of breast-cancer patients in the modern age.
A comparative study of genetic testing for breast and ovarian cancer in the United States and Britain that shows the importance of national context in the development and use of science and technology even in an era of globalization. In Building Genetic Medicine, Shobita Parthasarathy shows how, even in an era of globalization, national context is playing an important role in the development and use of genetic technologies. Focusing on the development and deployment of genetic testing for breast and ovarian cancer (known as BRCA testing) in the United States and Britain, Parthasarathy develops a comparative analysis framework in order to investigate how national “toolkits” shape both regulations and the architectures of technologies and uses this framework to assess the implications of new genetic technologies. Parthasarathy argues that differences in the American and British approaches to health care and commercialization of research led to the establishment of different BRCA services in the two countries. In Britain, the technology was available through the National Health Service as an integrated program of counseling and laboratory analysis, and was viewed as a potentially cost-effective form of preventive care. In the United States, although BRCA testing was initially offered by a number of providers, one company eventually became the sole provider of a test available to consumers on demand. Parthasarathy draws lessons for the future of genetic medicine from these cross-national differences, and discusses the ways in which comparative case studies can inform policy-making efforts in science and technology.
For nearly forty years, feminists and patient activists have argued that medicine is a deeply individualizing and depoliticizing institution. According to this view, medical practices are incidental to people’s transformation from patients to patient activists. The Biopolitics of Breast Cancer turns this understanding upside down. Maren Klawiter analyzes the evolution of the breast cancer movement to show the broad social impact of how diseases come to be medically managed and publicly administered. Examining surgical procedures, adjuvant therapies, early detection campaigns, and the rise in discourses of risk, Klawiter demonstrates that these practices created a change in the social relations-if not the mortality rate-of breast cancer that initially inhibited, but later enabled, collective action. Her research focuses on the emergence and development of new forms of activism that range from grassroots patient empowerment to environmental activism and corporate-funded breast cancer awareness. The Biopolitics of Breast Cancer opens a window onto a larger set of changes currently transforming medically advanced societies and ultimately challenges our understanding of the origins, politics, and future of the breast cancer movement. Maren Klawiter holds a PhD in sociology from the University of California, Berkeley. She is currently pursuing a law degree at Yale University.